Allogene Therapeutics EVP of R&D Rafael Amado resigns effective Dec 30, 2022

Allogene Therapeutics, Inc.

Rafael G. Amado, Executive Vice President of Research and Development, resigned.
Effective date of resignation: December 30, 2022.
Resignation is to pursue another opportunity; no replacement named.
Departure of top R&D executive may impact pipeline development.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rafael G. Amado

Executive Vice President of Research and Development

ALLO · Allogene Therapeutics, Inc.

Effective: 2022-12-30
Filed: January 3, 2023, 6:59 PM ET

On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rafael G. Amado resigned as Executive Vice President of Research and Development at Allogene Therapeutics, Inc..

Action: resigned
Role: Executive Vice President of Research and Development

Exact text from the filing

On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.